<< Back
March 5, 2019 at 8:00 AM EST

Ocular Therapeutix™ to Present at the Cowen and Company 39th Annual Health Care Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 5, 2019-- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Michael Goldstein, M.D., M.B.A., Chief Medical Officer of Ocular Therapeutix, will present at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019 at 8:40 AM ET at the Boston Marriott Copley Place Hotel in Boston, MA.

In addition to the presentation, the management team will host investor meetings at the conference. Investors attending the conference who are interested in meeting with Ocular Therapeutix management should contact their Cowen and Company representative.

A live webcast of the presentation can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is FDA-approved for the treatment of ocular pain following ophthalmic surgery. OTX-TP (intracanalicular travoprost insert) is an intracanalicular insert in Phase 3 clinical development for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. The Company’s earlier stage assets include OTX-TIC, an extended-delivery intracameral travoprost implant for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the treatment of retinal diseases. These intravitreal implants include OTX-TKI, containing a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an extended-delivery protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Source: Ocular Therapeutix, Inc.

Investors
Ocular Therapeutix
Donald Notman
Chief Financial Officer
dnotman@ocutx.com
or
Westwicke Partners
Chris Brinzey, 339-970-2843
chris.brinzey@westwicke.com

Media
Ocular Therapeutix
Scott Corning
Senior Vice President, Commercial
scorning@ocutx.com